NCT04433780View on ClinicalTrials.gov

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV

PHASE3CompletedINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

February 20, 2023

Study Completion Date

March 31, 2023

Conditions

HIV-1-infection

Interventions

DRUG

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate

DOR/3TC/TDF 100/300/300 mg once daily fixed-dose combination switched from either EFV/TDF/FTC or DTG/TDF/3TC

Trial Locations (2)

2196

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

Unknown

Sunnyside Office Park, Johannesburg

All Listed Sponsors

lead

Professor Francois Venter

OTHER

NCT04433780 - DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV | Biotech Hunter | Biotech Hunter